AbbVie Inc.
ABBV evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ABBV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ABBV
AbbVie Inc. is a global biopharmaceutical company focused on discovering and delivering innovative medicines across immunology, oncology, neuroscience, and aesthetics, with a Growth Platform that comprised 93% of total net revenues in 2025 following the U.S. Humira loss of exclusivity [sec · filed 2026-03-23].
Key risk: High debt leverage
BioSniper Score
Based on 6 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 42 pipeline candidates · 313 clinical trials · 56 catalysts · 51 FDA decisions for AbbVie Inc..
AbbVie Inc. is a global biopharmaceutical company focused on discovering and delivering innovative medicines across immunology, oncology, neuroscience, and aesthetics, with a Growth Platform that comprised 93% of total net revenues in 2025 following the U.S. Humira loss of exclusivity [sec · filed 2026-03-23].
- Total net revenues of $61.2 billion in 2025, driven by Growth Platform performance [sec · filed 2026-03-23].
- Growth Platform net revenues of $56.6 billion in 2025, an increase of 19.6% compared to 2024 [sec · filed 2026-03-23].
- Reported diluted EPS of $2.36 on a GAAP basis and adjusted diluted EPS of $10.00 in 2025 [sec · filed 2026-03-23].
- As of 2026-06-30, cash & equivalents $6,569.0M, total revenue $16,990.0M, net income $3,613.0M, shareholders' equity -$3,270.0M, total debt $62,481.0M [sec].
- Key pipeline assets include tavapadon for Parkinson's disease, trenibotulinumtoxinE for glabellar lines, and pivekimab sunirine for BPDCN, with regulatory applications submitted [sec · filed 2026-03-23].
What works
- Growth Platform net revenues increased 19.6% in 2025, with at least double-digit sales growth for nine key assets including nearly 50% growth for Skyrizi and 40% for Rinvoq [sec · filed 2026-03-23].
- AbbVie's Growth Platform comprised 93% of total net revenues in 2025, demonstrating successful transition following Humira LOE [sec · filed 2026-03-23].
- Generated operating cash flow of $18.8 billion in 2024, supporting R&D investment and pipeline development [sec · filed 2025-03-24].
What to weigh
- Shareholders' equity was negative -$3,270.0M as of 2026-06-30, indicating accumulated deficits exceed equity [sec].
- Total debt of $62,481.0M as of 2026-06-30 is high relative to cash of $6,569.0M, reflecting significant leverage [sec].
- Dependence on Growth Platform performance to offset Humira LOE; any slowdown in key assets could impact revenue [sec · filed 2026-03-23].
From the filings
Quoted directly from source documents.
Growth Platform comprised 93% of total net revenues in 2025
“AbbVie's Growth Platform comprised 93% of total net revenues in 2025”
SEC filings · March 23, 2026
Growth Platform net revenues increased 19.6% in 2025
“Growth Platform net revenues of $56.6 billion, an increase of 19.6% compared to 2024”
SEC filings · March 23, 2026
Reported diluted EPS of $2.36 on a GAAP basis in 2025
“Reported diluted EPS of $2.36 on a GAAP basis”
SEC filings · March 23, 2026
Total net revenues of $61.2 billion in 2025
“Total net revenues of $61.2 billion”
SEC filings · March 23, 2026
Catalyst timeline
- 2026-09-22 · Phase 2 Start for telisotuzumab combination study — Phase 2 open-label master protocol study evaluating safety and efficacy of telisotuzumab in combination regimens.
- 2026-09-30 · Phase 2 Start for pembrolizumab combination study — Phase 2 open-label randomized study evaluating safety, efficacy, and optimal dose of telisotuzumab with pembrolizumab.
- 2026-11-01 · Phase 3 Topline for multiple-attack study — Randomized, double-blind, placebo-controlled, multiple-attack study with open-label extension.
- 2026-12-01 · Phase 3 Topline for placebo-controlled study — Multicenter, randomized, double-blind placebo-controlled study to evaluate efficacy and safety.
- 2026-12-31 · Phase 2 Readout for hidradenitis suppurativa — Phase 2 readout for hidradenitis suppurativa (HS).
- 2027-01-01 · Phase 3 Topline for randomized study — Randomized, placebo-controlled, double-blind study evaluating safety and efficacy.
- 2027-03-01 · Phase 3 Topline for cariprazine — 6-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study of cariprazine.
- 2027-03-01 · Phase 3 Topline for efficacy assessor-blinded study — Phase 3b/4 randomized, open-label, efficacy assessor-blinded study evaluating efficacy and safety.
Risks & what to watch (3)›
Key risks
- High debt leverage — Total debt of $62,481.0M as of 2026-06-30 vs. cash $6,569.0M, indicating significant financial leverage [sec].
- Negative shareholders' equity — Shareholders' equity of -$3,270.0M as of 2026-06-30 reflects accumulated deficits exceeding equity [sec].
- Dependence on Growth Platform — 93% of revenue from Growth Platform; any slowdown in key assets could materially impact results [sec · filed 2026-03-23].
What to watch
- Phase 3 topline data for multiple pipeline programs expected in late 2026 and early 2027, including cariprazine and other assets [upcoming catalysts].
- Phase 2 readout for hidradenitis suppurativa expected by end of 2026 [upcoming catalysts].
- Regulatory decisions on tavapadon for Parkinson's disease and trenibotulinumtoxinE for glabellar lines, with applications submitted [sec · filed 2026-03-23].
- Performance of key Growth Platform assets Skyrizi and Rinvoq in upcoming quarters [sec · filed 2026-03-23].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run AbbVie Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AbbVie Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
OCF $3.4B · Net income $3.6B · Debt/OCF 4.1×
Lead: Approved
42 candidates
56 upcoming, next in ~23d
0 buys · 2 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4,057
Total value held
$284.52B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 229,760,648 | $49.97B |
| blackrock, inc. | 150,749,625 | $32.79B |
| state street corp | 81,217,516 | $17.66B |
| vanguard portfolio management llc | 49,523,078 | $10.77B |
| geode capital management, llc | 46,737,581 | $10.14B |
| morgan stanley | 38,016,774 | $8.27B |
| bank of america corp /de/ | 23,936,943 | $5.21B |
| fmr llc | 21,762,703 | $4.73B |
| northern trust corp | 21,211,382 | $4.61B |
| goldman sachs group inc | 16,437,679 | $3.58B |
Showing top 10 of 4,057 institutional holders of AbbVie Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 19, 2026- % of float
- 1.3%
- Days to cover
- 3.0
- Shares short
- 20,907,964
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ABBV short interestGovernance
Frequently asked questions
What is the AI investment thesis for AbbVie Inc.?
AbbVie Inc. is a global biopharmaceutical company focused on discovering and delivering innovative medicines across immunology, oncology, neuroscience, and aesthetics, with a Growth Platform that comprised 93% of total net revenues in 2025 following the U.S. Humira loss of exclusivity [sec · filed 2026-03-23].
What is AbbVie Inc.'s lead drug candidate?
AbbVie Inc.'s most advanced tracked candidate is acuvail (Approved).
What is AbbVie Inc.'s next catalyst?
AbbVie Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 2, Open-Label, Master Protocol Study to Evaluate Safety and Efficacy of Treatment Combinatio" — expected September 22, 2026.
Who is the CEO of AbbVie Inc.?
Mr. Robert A. Michael CPA is the chief executive officer of AbbVie Inc. (ABBV).
Where is AbbVie Inc. headquartered?
AbbVie Inc. (ABBV) is headquartered in North Chicago, IL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.